Bliss GVS Pharma Limited has fixed Wednesday, July 08, 2026, as the record date to determine shareholder eligibility for the final dividend of ₹1.00 per equity share for the financial year ended March 31, 2026. The dividend, recommended by the Board of Directors on May 12, 2026, is subject to shareholder approval at the 41st Annual General Meeting (AGM) scheduled for Wednesday, July 15, 2026, at 11:00 a.m. IST via video conferencing. The company has submitted the newspaper publication for the AGM to the National Stock Exchange of India and BSE Limited.

The AGM will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM) in compliance with the Ministry of Corporate Affairs and SEBI circulars. Shareholders attending via VC/OVAM will be counted for quorum purposes under Section 103 of the Companies Act, 2013. Electronic copies of the Notice of AGM and the Annual Report for FY26 will be sent to registered email addresses and made available on the company's website and stock exchange portals.

The company outlined the tax deduction at source (TDS) norms applicable to the dividend. For resident shareholders with a valid Permanent Account Number (PAN), TDS will be deducted at 10%. If the PAN is invalid, not linked with Aadhaar, or unavailable, the deduction rate increases to 20% under Section 397(2) of the Income Tax Act, 2025. Resident individuals are exempt from TDS if their total dividend income does not exceed ₹10,000 or if they submit valid declarations such as Form 121 or exemption certificates.

For non-resident shareholders, the domestic tax law mandates a withholding tax rate of 20%, plus applicable surcharge and cess. Shareholders may opt for beneficial rates under the Double Tax Avoidance Agreement (DTAA) by submitting a Tax Residency Certificate (TRC), digital Form 41, and a self-declaration of treaty eligibility. The company clarified that it is not obligated to apply DTAA rates if documents are incomplete or unsatisfactory.

Shareholders must update their bank account details and KYC information to facilitate timely dividend payments. The final dividend will be paid electronically to those with updated bank details. Any documents received after the record date will be accepted at the company's sole discretion, and tax deducted at a higher rate due to missing information can be claimed as a refund while filing income tax returns.

Key Dividend and AGM Details

Anupam Rasayan India Limited has filed the Draft Letter of Offer with the Securities and Exchange Board of India (SEBI) to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited, representing 26.00% of the expanded voting share capital. The offer price is fixed at ₹299.00 per equity share, aggregating to a total consideration of ₹829,03,27,552.00. This mandatory open offer is triggered by a share purchase agreement dated May 23, 2026, wherein the acquirer agreed to purchase 4,58,03,024 equity shares, representing 43.30% of the equity share capital, from the existing promoters and public shareholders.

The transaction is being made in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Upon completion of the underlying transaction and the open offer, Anupam Rasayan India Limited will gain control over Bliss GVS Pharma Limited and will be designated as the promoter. The existing promoter group will be reclassified as public shareholders. The acquirer has stated that it has no intention to delist the target company following this offer.

Offer Details and Schedule

The tentative schedule for the open offer outlines key dates for the process. The identified date for determining eligible shareholders is July 2, 2026. The tendering period, during which shareholders can offer their shares, is set to commence on July 16, 2026, and conclude on July 29, 2026. The last date for the payment of consideration or refund of shares to shareholders is August 12, 2026.

Financial Arrangements and Pricing

The offer price of ₹299.00 per share has been determined in accordance with Regulation 8(2) of the SEBI (SAST) Regulations, being the highest of the negotiated price under the share purchase agreement and the volume weighted average market price. To secure the offer, the acquirer has deposited ₹160,00,00,000.00 into an escrow account with Axis Bank Limited. Swati Kedar Kothari and Co., Chartered Accountants, have certified that the acquirer has adequate financial resources to fulfill the obligations under the offer.

The acquirer has arranged financing through cash and cash equivalents amounting to ₹394.00 crore, callable money of ₹644.00 crore, and a non-binding high confidence letter for potential acquisition financing of ₹2,000.00 crore. The open offer is not conditional upon any minimum level of acceptance.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE930P01018/93dfa81b-5384-4b2e-a2bd-02b4241b9c6f.pdf